.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Covington
McKinsey
Accenture
Healthtrust
Boehringer Ingelheim
Argus Health
Mallinckrodt
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,183,264

« Back to Dashboard

Which drugs does patent 7,183,264 protect, and when does it expire?


Patent 7,183,264 protects LEXISCAN and is included in one NDA. There has been one Paragraph IV challenge on Lexiscan.

This patent has twenty-seven patent family members in twenty-three countries.

Summary for Patent: 7,183,264

Title:N-pyrazole A2A receptor agonists
Abstract:2-adenosine N-pyrazole compounds having the following formula: ##STR00001## and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
Inventor(s): Zablocki; Jeff (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Gurgaon, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:10/652,378
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AstellasLEXISCANregadenosonSOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
AstellasLEXISCANregadenosonSOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
AstellasLEXISCANregadenosonSOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF MYOCARDIAL IMAGING
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,183,264

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,045,519N-pyrazole A.sub.2A receptor agonists► Subscribe
6,403,567 N-pyrazole A2A adenosine receptor agonists► Subscribe
8,569,260N-pyrazole A.sub.2A receptor agonists► Subscribe
7,655,637N-pyrazole A.sub.2A receptor agonists► Subscribe
8,278,435N-pyrazole A2A receptor agonists► Subscribe
7,144,872N-pyrazole A.sub.2A receptor agonists► Subscribe
6,642,210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,183,264

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway2011002► Subscribe
New Zealand516334► Subscribe
Turkey200200588► Subscribe
TaiwanI230161► Subscribe
Portugal1189916► Subscribe
Norway20016350► Subscribe
Norway322457► Subscribe
MexicoPA01013325► Subscribe
Luxembourg91785► Subscribe
South Korea100463300► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Chubb
Cerilliant
Johnson and Johnson
AstraZeneca
Healthtrust
Federal Trade Commission
Harvard Business School
Fuji
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot